Longeveron Advances $10B+ Pipeline with FDA-Validated Trials for Alzheimer's, HLHS

Summary

The article discusses Longeveron Inc.'s progress and future plans for its stem cell therapy, Lomecel-B™, especially in treating hypoplastic left heart syndrome (HLHS) and Alzheimer's. Despite potential FDA approval and large market opportunities, Longeveron seeks additional funding. While "natural medicine" isn't explicitly mentioned, Lomecel-B™ fits this concept by using biologically sourced therapies, relevant to tags like the FDA, priority review, and heart syndromes.